Vera Therapeutics Inc.

VERA | NASDAQ

Price Alert Chart Builder DCF Calculator

$34.72

+$0.47 (+1.37%)

Sep 22, 2026, 9:35 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.37%

(1D)

Rating

Updated: Aug 20, 2026

19.7

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $2.49B

1D Range

34.44 34.75

52W Range

23.05 56.05

Valuation (TTM)

PE -5.84

PB 6.03

EV/EBITDA -5.22

Valuation (NTM)

Forward PE N/A

Forward PEG 0.20

Price Target $86.75

Cash Flow

FCF Yield -13.8%

SBC Adj. FCF Yield -15.8%

SBC Impact -14.7%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y -46.5% | -20.9%

FCF 3Y | 5Y -53.0% | -46.5%

Returns

ROA -75.4%

ROE -84.1%

ROIC -85.8%

Financial Health

Net Cash

$423.93M

Current Ratio 10.92

Interest Coverage -36.93

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United St...

Sector Healthcare

Industry Biotechnology

Employees 361

IPO Date May 13, 2021

Website veratx.com

Fiscal Year January - December

Full Company Profile

Latest News

6 days ago · seekingalpha.com

Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

7 days ago · benzinga.com

What's Going on With Vera Therapeutics Stock on Tuesday?

Vera Therapeutics Inc. (NASDAQ:VERA) shares are trading lower on Tuesday, after initially spiking higher, amid increased volatility after the company announced data from the ORIGIN 3 trial.

7 days ago · barrons.com

Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results

Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna.

7 days ago · invezz.com

Why is Vera Therapeutics stock reversing its premarket gains?

Vera Therapeutics (VERA) shares ripped higher in premarket trading on September 15 as investors reacted to landmark clinical data. The biopharmaceutical firm announced that its lead therapy TRUTAKNA (atacicept-vymj) met all primary and secondary endpoints in the final 104-week efficacy analysis of its Phase 3 ORIGIN 3 trial for primary IgA nephropathy (IgAN).

7 days ago · schaeffersresearch.com

Vera Stock Slides Despite Positive Phase 3 Results

Vera Therapeutics (NASDAQ:VERA) stock is down 2% to trade at $33.34, reversing earlier gains after disclosing positive late-stage ORIGIN 3 trial results for the company's TRUTAKNA drug.

7 days ago · globenewswire.com

Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy

Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR, Prevented IgAN Disease Progression Through 2 Years in ORIGIN 3 Final Analysis

21 days ago · globenewswire.com

Vera Therapeutics to Participate at Upcoming Investor Conferences

BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences.

1 month ago · seekingalpha.com

Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy

Vera Therapeutics is upgraded to Buy following TRUTAKNA's FDA approval and encouraging eGFR data. The FDA's exploratory eGFR analysis shows stable kidney function with TRUTAKNA, supporting the bull case ahead of full phase 3 data in Q3 2026. TRUTAKNA faces competition from Otsuka's VOYXACT and Vertex's povetacicept but enjoys a commercial head start and broad label.

3 months ago · globenewswire.com

Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner

BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer position.